Clinical Trial Update: A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma [Phase 2]

View source ↗

Summary

Phase II trial evaluating adding tocilizumab to ipilimumab and nivolumab for unresectable stage III/IV melanoma. Results were posted on 2024-10-09.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• OPDIVO (nivolumab)
• Tocilizumab (tocilizumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: NYU Langone Health | Conditions: Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-10-09